← Back to Clinical Trials
Recruiting NCT02897297

NCT02897297 Myeloproliferative Neoplastic Diseases Observatory From Brest

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02897297
Status Recruiting
Phase —
Sponsor University Hospital, Brest
Condition Polycythemia Vera
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2015-09-01
Primary Completion 2025-09-30

Trial Parameters

Condition Polycythemia Vera
Sponsor University Hospital, Brest
Study Type OBSERVATIONAL
Phase N/A
Enrollment 1,000
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2015-09-01
Completion 2025-09-30

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

All patients diagnosed or followed in Brest University Hospital for Philadelphia negative myeloproliferative neoplasms will be included in this observational study. Myeloproliferative neoplasms recorded included: polycythemia vera, essential Thrombocythemia and Primary Myelofibrosis. This is a not interventional study. Alive patients need to sign a non-opposition consent form. Patients will be followed until last news (death, change of reference centre...).

Eligibility Criteria

Inclusion Criteria: * Patients with essentiel thrombocythemia, polycythemia vera or primary myelofibrosis * Signature of the non-opposition consent form Exclusion Criteria: * None

Related Trials

VIEW ON CLINICALTRIALS.GOV ↗ MORE POLYCYTHEMIA VERA TRIALS
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology